Bristol-Myers Squibb Company / Immatics N.V.

Solid Tumors (Allogeneic TCR/CAR-T Cell Therapy)

200K US cases/yr · $18.0B Global cell and gene therapy oncology market 2030 forecast · ~3-5% Estimated solid tumor patient access to commercial autologous CAR-T (vs heme >50%)

Disease Overview

The expanded BMS/Immatics alliance targets multiple solid tumor indications addressable by allogeneic T cell receptor (TCR) and chimeric antigen receptor (CAR) cell therapies engineered from gamma-delta donor T cells. Solid tumors represent the largest unmet need in cell therapy — autologous CAR-T has transformed B-cell hematologic malignancies but has not meaningfully translated to solid tumors due to antigen heterogeneity, tumor microenvironment immunosuppression, and tonic T-cell exhaustion. The collective U.S. addressable population across cancers expressing Immatics' XPRESIDENT-discovered targets (PRAME, MAGE-A4, MAGE-A1, KK-LC-1, others) exceeds 200,000 incident cases annually, spanning melanoma (~100,000 U.S. cases), NSCLC (~236,000 U.S. cases), head and neck cancer (~67,000 U.S. cases), ovarian (~20,000), synovial sarcoma (~1,000), and uterine carcinosarcoma. Allogeneic 'off-the-shelf' cell therapy promises lower COGS, scalable inventory, and immediate dosing versus the 3-4 week vein-to-vein time of autologous platforms. Pricing for autologous CAR-T sits at $400-475K per dose; allogeneic products targeting heme malignancies have priced at $300-400K, with solid tumor pricing yet to be established but expected to anchor at premium oncology levels.

Competitive Landscape

The allogeneic cell therapy landscape for solid tumors is increasingly crowded but largely pre-pivotal. Allogeneic CAR/TCR-T platforms include Immatics' ACTallo gamma-delta T cell engineering (BMS partnered, plus IMA401 autologous TCR-bispecific in Phase 1), Allogene Therapeutics' AlloCAR-T (heme-anchored, expanding to solid), Adicet Bio's gamma-delta CAR-T platform (ADI-001 in lymphoma plus solid tumor preclinical), Caribou Biosciences' allogeneic CRISPR-edited platform, Precision BioSciences' ARCUS allogeneic CAR-T, Atara Biotherapeutics' EBV-targeted T cell platform, and Takeda/MD Anderson's gamma-delta program. Adaptimmune (afami-cel, autologous TCR-T, MAGE-A4) achieved FDA approval in synovial sarcoma in August 2024 — the first solid tumor TCR-T. Adaptimmune's letetresgene autoleucel (NY-ESO-1, GSK-partnered) was discontinued in 2023. The differentiation thesis for ACTallo gamma-delta is non-MHC-restricted recognition, lower graft-versus-host risk, and inherent innate-like cytotoxicity that may overcome solid-tumor exhaustion biology better than alpha-beta T cells. Other competitive overlays include autologous TCR-T platforms from GSK (legacy NY-ESO-1 and MAGE-A4 programs), TScan Therapeutics, and Achilles Therapeutics targeting tumor-specific neoantigens. The ACTallo deal also competes against next-generation NK-cell platforms from Fate Therapeutics, Nkarta, and Century Therapeutics that share off-the-shelf scalability without alpha-beta T-cell GVH risk. BMS's solid-tumor cell therapy strategy uniquely combines Celgene-acquired heme assets (Breyanzi, Abecma) with this Immatics solid-tumor allogeneic bench, positioning the company across both autologous and allogeneic modalities.